MAP2K1 and melanoma: In contrast, A2058 melanoma cells are resistant to vemurafenib (Fig S3c), possibly due to a MAP2K1 P124S mutation45, but remain sensitive to the combination of dabrafenib + trametinib (Dab + Tram) (Fig S3d).